H2AX and urinary bladder carcinoma: To test whether these synthesized compounds, WYC02 and WYC0209, would enhance cisplatin-induced DNA damage, we initially treated bladder cancer cells with WYC02 or WYC0209 and measured the level of p-histone H2A.X.